Rasagiline Tartrate
-
API Product :
Rasagiline Tartrate
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Anti-Parkinson Drugs
-
Originator :
Lundbeck
-
CAS No. :
136236-51-6
-
Trade Name. :
AZILECT
-
Molecular Weight :
171.238 g/mol
-
Molecular Formula :
C12H13N
Application
Rasagiline Tablets are used for the treatment of Parkinson's disease. It can be used together with or without levodopa (another medicine that is used to treat Parkinson's disease). This medicine contains the active ingredient, rasagiline tartrate.
General Description
Rasagiline (Azilect, TVP-1012, N-propargyl-1(R)-aminoindan[1]) is an irreversible inhibitor of monoamine oxidase-B[2] used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.[3] The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion – Israel Institute of Technology in Israel and the drug company, Teva Pharmaceutical, identified the R-isomer as the active form of the drug.